Abstract:Objective: Drug-induced liver injury (DILI) is a major failure mode in pharmaceutical development. This study aims to address the limitations of existing preclinical models by introducing a high-throughput, microfluidic liver-on-a-chip system, termed as "Curio Barrier Liver Chips," seeded with human liver organoids to enable metabolic and phenotypic morphologic characterization. Methods: Curio Barrier liver chips, fabricated in an 8x2 well configuration, were utilized to establish 3D liver organoid cultures. Human-induced pluripotent stem cells (iPSCs) were differentiated into hepatic-like organoids (HLOs), and their viability, liver-specific functions, and pharmacological responses were assessed over 28 days. Results: The Curiochips successfully maintained liver physiology and function, showing strong albumin secretion and cytochrome P450 (CYP) activities through 28 days. Unlike traditional models requiring millimolar drug concentrations to detect hepatotoxicity, this platform showed increased sensitivity for APAP and FIAU at micromolar concentrations. In situ differentiation of foregut spheroids to liver organoids was also achieved, further simplifying the establishment of liver chips. Furthermore, the chips demonstrated viability, function and DILI responsiveness for 28 days making this an improved model for studying idiosyncratic DILI with prolonged drug exposure and high-throughput capabilities compared to other available systems or primary human hepatocytes. Conclusions: The Curiochips offer an advanced, miniaturized in vitro model for early-stage drug development and a sensitive, responsive and cost-effective means to detect direct hepatotoxicity. The high-throughput capability, coupled with robust functionality and pharmacological responses make it a promising tool for improving the prediction and understanding of DILI mechanisms in general and those that required prolonged drug exposure. The model also opens new avenues for research in other chronic liver diseases. Keywords: Drug-induced liver injury, hepatotoxicity, microfluidic liver chips, microphysiologic liver model, high-throughput screening, iPSC-derived hepatic-like organoids, chronic DILI model, Curiochips.

Microengineered Bioartificial Liver Chip for Drug Toxicity Screening

Metastasis-on-a-chip Mimicking the Progression of Kidney Cancer in the Liver for Predicting Treatment Efficacy

Synergistic Modulation of a Tunable Microenvironment to Fabricate a Liver Fibrosis Chip for Drug Testing.

Hydrogel Microfluidic‐based Liver‐on‐a‐chip: Mimicking the Mass Transfer and Structural Features of Liver

A pumpless liver-on-a-chip for drug hepatotoxicity analysis

A 3D bio-printed spheroids based perfusion in vitro liver on chip for drug toxicity assays

Design and fabrication of an integrated 3D dynamic multicellular liver-on-a-chip and its application in hepatotoxicity screening

Liver-on-a-Chip Integrated with Label-Free Optical Biosensors for Rapid and Continuous Monitoring of Drug-Induced Toxicity

On-Chip Construction of Liver Lobule-like Microtissue and Its Application for Adverse Drug Reaction Assay.

A perfusion incubator liver chip for 3D cell culture with application on chronic hepatotoxicity testing

Integration of single-layer skin hollow fibers and scaffolds develops a three-dimensional hybrid bioreactor for bioartificial livers

Three-dimensional Culture in a Microgravity Bioreactor Improves the Engraftment Efficiency of Hepatic Tissue Constructs in Mice

A High-Throughput Microphysiological Liver Chip System to Model Direct and Idiosyncratic Drug-Induced Liver Injury Using Human Liver Organoids

Efficient Drug Screening and Nephrotoxicity Assessment on Co-culture Microfluidic Kidney Chip

Development of a Biomimetic Liver Tumor-on-a-chip Model Based on Decellularized Liver Matrix for Toxicity Testing.

Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology

Three-dimensional Culture of Hepatocytes for Prediction of Drug-Induced Hepatotoxicity

A lung/liver-on-a-chip platform for acute and chronic toxicity studies

Prediction of metabolism-induced hepatotoxicity on three-dimensional hepatic cell culture and enzyme microarrays

Microfluidic human physiomimetic liver model as a screening platform for drug induced liver injury

Liver Spheroids on Chips as Emerging Platforms for Drug Screening